康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究(1)
摘 要：目的 探讨康艾注射液配合多西他赛、顺铂治疗晚期非小细胞肺癌的客观疗效和安全性。方法 将解放军武汉总医院2015年2月～2018 年2月收治的100例晚期非小细胞肺癌患者按随机数字表法分为两组，每组50例。对照组给予多西他赛、顺铂化疗，治疗组在对照组基础上加康艾注射液治疗。连续治疗2个疗程后评估疗效、生活质量、中医症状和不良反应。结果 治疗组的有效率为46.00%，高于照组的44.00%，但差异无统计学意义(P>0.05);治疗组在生活质量改善优于对照组(68.00% vs 48.00%)(P<0.05)。治疗组纳呆、神疲乏力、呕吐三组中医症状均较对照组有改善(P<0.05)。治疗组化疗不良反应减轻方面优于对照组(P<0.05)。结论 康艾注射液聯合多西他赛、顺铂治疗晚期非小细胞肺癌在稳定性、改善生活质量、减轻毒副反应方面存在一定优势，值得进一步深入研究。
关键词：康艾注射液;联合化疗;非小细胞肺癌;生存质量
中图分类号：R734.2 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.24.033
, 百拇医药
文章编号：1006-1959(2018)24-0115-03
Abstract：Objective To investigate the efficacy and safety of Kang'ai injection combined with docetaxel and cisplatin in the treatment of advanced non-small cell lung cancer. Methods 100 patients with advanced non-small cell lung cancer treated in PLA Wuhan General Hospital from February 2015 to February 2018 were divided into control group and treatment group according to the method of random digital table， 50 cases in each group.The control group was treated with docetaxel and cisplatin， and the treatment group was treated with Kang'ai injection on the basis of the control group.We evaluated the efficacy， quality of life， TCM symptoms and adverse reactions after 2 consecutive courses of treatment.Results The effective rate of the treatment group was 46.00%， which was higher than that of the radiation group 44.00%， but the difference was not statistically significant(P>0.05).The improvement of quality of life in the treatment group was better than that in the control group (68. 00% vs 48. 00%) (P<0. 05).The symptoms of TCM in the treatment group were improved compared with the control group(P<0.05). The side effect of chemotherapy in the treatment group was better than that in the control group(P<0.05).Conclusion Kang'ai injection combined with docetaxel and cisplatin in the treatment of advanced non-small cell lung cancer has some advantages in terms of stability， improving quality of life and alleviating side effects， which is worthy of further study.
, 百拇医药
Key words：Kang'ai Injection; Non-small cell lung cancer; Quality of life
根据2015年中国癌症统计数据显示，肺癌是我国癌症相关性死亡的主要原因，且死亡人数在不断增加[1]。肺癌在确诊时约85%为非小细胞肺癌(non small cell lung cancer，NSCLC)，除少数患者可经手术切除外，多数患者诊断时已达晚期(ⅢB/Ⅳ期)[2]。化疗是晚期NSCLC治疗的主要手段之一，但化疗在杀伤肿瘤细胞的同时可能会对机体造成不同程度的损害。中医药在保护机体，增强机体免疫力方面有独到的疗效。康艾注射液是常用的中药抗肿瘤注射液，临床广泛应用于肺癌、肝癌、直肠癌等恶性肿瘤的治疗。本研究旨在观察康艾注射液联合化疗治疗晚期NSCLC的有效性和安全性，深入了解其作用特点，为临床合理应用提供循证依据。, http://www.100md.com(付红星 冯小剑 彭文苗 饶智国)
关键词：康艾注射液;联合化疗;非小细胞肺癌;生存质量
中图分类号：R734.2 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.24.033
, 百拇医药
文章编号：1006-1959(2018)24-0115-03
Abstract：Objective To investigate the efficacy and safety of Kang'ai injection combined with docetaxel and cisplatin in the treatment of advanced non-small cell lung cancer. Methods 100 patients with advanced non-small cell lung cancer treated in PLA Wuhan General Hospital from February 2015 to February 2018 were divided into control group and treatment group according to the method of random digital table， 50 cases in each group.The control group was treated with docetaxel and cisplatin， and the treatment group was treated with Kang'ai injection on the basis of the control group.We evaluated the efficacy， quality of life， TCM symptoms and adverse reactions after 2 consecutive courses of treatment.Results The effective rate of the treatment group was 46.00%， which was higher than that of the radiation group 44.00%， but the difference was not statistically significant(P>0.05).The improvement of quality of life in the treatment group was better than that in the control group (68. 00% vs 48. 00%) (P<0. 05).The symptoms of TCM in the treatment group were improved compared with the control group(P<0.05). The side effect of chemotherapy in the treatment group was better than that in the control group(P<0.05).Conclusion Kang'ai injection combined with docetaxel and cisplatin in the treatment of advanced non-small cell lung cancer has some advantages in terms of stability， improving quality of life and alleviating side effects， which is worthy of further study.
, 百拇医药
Key words：Kang'ai Injection; Non-small cell lung cancer; Quality of life
根据2015年中国癌症统计数据显示，肺癌是我国癌症相关性死亡的主要原因，且死亡人数在不断增加[1]。肺癌在确诊时约85%为非小细胞肺癌(non small cell lung cancer，NSCLC)，除少数患者可经手术切除外，多数患者诊断时已达晚期(ⅢB/Ⅳ期)[2]。化疗是晚期NSCLC治疗的主要手段之一，但化疗在杀伤肿瘤细胞的同时可能会对机体造成不同程度的损害。中医药在保护机体，增强机体免疫力方面有独到的疗效。康艾注射液是常用的中药抗肿瘤注射液，临床广泛应用于肺癌、肝癌、直肠癌等恶性肿瘤的治疗。本研究旨在观察康艾注射液联合化疗治疗晚期NSCLC的有效性和安全性，深入了解其作用特点，为临床合理应用提供循证依据。, http://www.100md.com(付红星 冯小剑 彭文苗 饶智国)